# US 2008/0306032 A1 · 7-Phenyl-Substituted Tetracycline Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306032 A1
- Document ID: US20080306032A1
- Status: Published application
- Kind: A1
- Application number: 12/183,711
- Filed: 2008-07-31
- Published: 2008-12-11
- Earliest claimed: 2000-06-16
- Inventors: Mark L. Nelson; Mohamed Y. Ismail
- Web page: https://patentgrep.com/patent/US20080306032A1

## CPC

- A61K 31/65: Tetracyclines
- A61P 31/04: Antibacterial agents
- C07C 237/26: of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described.

## Claims

### Claim 1

A 7-substituted tetracycline compound which is substantially free of positional isomers, said compound having the formula:
wherein:
R4 and R4′ are each alkyl;
R5 is hydrogen, hydroxyl, or a prodrug moiety;
R6 and R6′ are each independently hydrogen, hydroxyl, alkyl, or taken together, alkenyl;
R7 is halo substituted, N-substituted or unsubstituted phenyl, and pharmaceutically acceptable salts thereof, wherein said tetracycline compound is substantially free of positional isomers.

### Claim 2 (depends on 1)

The compound of claim 1, wherein R5, R6 and R6′ are each hydrogen and R4 and R4′ are each methyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R7 is unsubstituted phenyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R7 is 2-substituted phenyl.

### Claim 5 (depends on 4)

The compound of claim 4, wherein said compound is selected from the group consisting of 7-(2-fluorophenyl) sancycline, 7-(2-chlorophenyl) sancycline, 7-(2-bromophenyl) sancycline, and 7-(2-iodophenyl) sancycline.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R7 is 3-substituted phenyl.

### Claim 7 (depends on 6)

The compound of claim 6, wherein said compound is selected from the group consisting of 7-(3-fluorophenyl) sancycline, 7-(3-chlorophenyl) sancycline, 7-(3-bromophenyl) sancycline, and 7-(3-iodophenyl) sancycline.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R7 is 4-substituted phenyl.

### Claim 9 (depends on 8)

The compound of claim 8, wherein said compound is selected from the group consisting of 7-(4-fluorophenyl) sancycline, 7-(4-chlorophenyl) sancycline, 7-(4-bromophenyl) sancycline, 7-(4-iodophenyl) sancycline, 7-(4-trichloromethylphenyl) sancycline, 7-(4-trifluoromethylphenyl) sancycline, 7-(4-tribromomethylphenyl) sancycline, and 7-(4-triiodomethylphenyl) sancycline.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R7 is 2-N-substituted phenyl.

### Claim 11 (depends on 10)

The compound of claim 10, wherein said 2-N-substituted phenyl is substituted with a nitro group.

### Claim 12 (depends on 11)

The compound of claim 11, wherein said compound is 7-(2-nitrophenyl) sancycline.

### Claim 13 (depends on 10)

The compound of claim 10, wherein said 2-N-substituted phenyl is 2-amino substituted.

### Claim 14 (depends on 13)

The compound of claim 13, wherein said 2-amino substituent is dialkylamino.

### Claim 15 (depends on 14)

The compound of claim 14, wherein said dialkyl amino group is dimethylamino.

### Claim 16 (depends on 13)

The compound of claim 13, wherein said compound is selected from the group consisting of 7-(2-aminophenyl) sancycline, 7-(2-N,N,-dimethylaminophenyl) sancycline, 7-(2-N,N,-diethylaminophenyl) sancycline, 7-(2-N,N,-dipropylaminophenyl) sancycline, and 7-(2-N,N,-dibutylaminophenyl) sancycline.

### Claim 17 (depends on 1)

The compound of claim 1, wherein R7 is 3-N-substituted phenyl.

### Claim 18 (depends on 17)

The compound of claim 17, wherein said 3-N-substituted phenyl is substituted with a nitro group.

### Claim 19 (depends on 18)

The compound of claim 18, wherein said compound is 7-(3-nitrophenyl) sancycline.

### Claim 20 (depends on 17)

The compound of claim 17, wherein said 3-N-substituted phenyl is 3-amino substituted.

### Claim 21 (depends on 20)

The compound of claim 20, wherein said 3-amino substituent is dialkylamino.

### Claim 22 (depends on 21)

The compound of claim 21, wherein said dialkyl amino group is dimethylamino.

### Claim 23 (depends on 20)

The compound of claim 20, wherein said compound is selected from the group consisting of 7-(3-aminophenyl) sancycline, 7-(3-N,N,-dimethylaminophenyl) sancycline, 7-(3-N,N,-diethylaminophenyl) sancycline, 7-(3-N,N,-dipropylaminophenyl) sancycline, and 7-(3-N,N,-dibutylaminophenyl) sancycline.

### Claim 24 (depends on 1)

The compound of claim 1, wherein R7 is 4-N-substituted phenyl.

### Claim 25 (depends on 24)

The compound of claim 24, wherein said 4-N-substituted phenyl is substituted with a nitro group.

### Claim 26 (depends on 25)

The compound of claim 25, wherein said compound is 7-(4-nitrophenyl) sancycline.

### Claim 27 (depends on 24)

The compound of claim 24, wherein said 4-substituted phenyl is 4-amino substituted.

### Claim 28 (depends on 27)

The compound of claim 27, wherein said 4-amino substituent is dialkyl.

### Claim 29 (depends on 28)

The compound of claim 28, wherein said dialkyl amino group is dimethyl.

### Claim 30 (depends on 29)

The compound of claim 29, wherein said compound is 7-(4-aminophenyl) sancycline, 7-(4-N,N,-dimethylaminophenyl) sancycline, 7-(4-N,N,-diethylaminophenyl) sancycline, 7-(4-N,N,-dipropylaminophenyl) sancycline, or 7-(4-N,N,-dibutylaminophenyl) sancycline.

### Claim 31

A tetracycline compound which is substantially free of positional isomers, wherein said tetracycline compound is 7,9-diphenyl sancycline, and pharmaceutically acceptable salts thereof, wherein said tetracycline compound is substantially free of positional isomers.

### Claim 32 (depends on 1, 31)

The compound of any one of claims 1 or 31, wherein said compound is at least 75% free of positional isomers.

### Claim 33 (depends on 32)

The compounds of claim 32, wherein said compound is at least 80% free of positional isomers.

### Claim 34 (depends on 33)

The compounds of claim 33, wherein said compound is at least 85% free of positional isomers.

### Claim 35 (depends on 34)

The compound of claim 34, wherein said compound is at least 90% free of positional isomers.

### Claim 36 (depends on 35)

The compound of claim 35, wherein said compound is at least 95% free of positional isomers.

### Claim 37

A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal a 7-substituted tetracycline compound, which is substantially free of positional isomers, of formula (I):
wherein:
R4 and R4′ are each alkyl;
R5 is hydrogen, hydroxyl, or a prodrug moiety;
R6 and R6′ are each independently hydrogen, hydroxyl, alkyl, or taken together, alkenyl;
R7 is halo substituted, N-substituted or unsubstituted phenyl; and pharmaceutically acceptable salts thereof, such that the tetracycline responsive state is treated, wherein said tetracycline compound is substantially free of positional isomers.

### Claim 38 (depends on 37)

The method of claim 37, wherein R5, R6 and R6′ are each hydrogen and R4 and R4′ are each methyl.

### Claim 39 (depends on 38)

The method of claim 38, wherein R7 is unsubstituted phenyl.

### Claim 40 (depends on 38)

The method of claim 38, wherein R7 is 2-substituted phenyl.

### Claim 41 (depends on 40)

The method of claim 40, wherein said compound is selected from the group consisting of 7-(2-fluorophenyl) sancycline, 7-(2-chlorophenyl) sancycline, 7-(2-bromophenyl) sancycline, 7-(2-iodophenyl) sancycline, 7-(2-nitrophenyl) sancycline, 7-(2-aminophenyl) sancycline, 7-(2-N,N,-dimethylaminophenyl) sancycline, 7-(2-N,N,-diethylaminophenyl) sancycline, 7-(2-N,N,-dipropylaminophenyl) sancycline, and 7-(2-N,N,-dibutylaminophenyl) sancycline.

### Claim 42 (depends on 38)

The method of claim 38, wherein R7 is 3-substituted phenyl.

### Claim 43 (depends on 42)

The method of claim 42, wherein said compound is selected from the group consisting of 7-(3-fluorophenyl) sancycline, 7-(3-chlorophenyl) sancycline, 7-(3-bromophenyl) sancycline, 7-(3-iodophenyl) sancycline, 7-(3-nitrophenyl) sancycline, 7-(3-aminophenyl) sancycline, 7-(3-N,N,-dimethylaminophenyl) sancycline, 7-(3-N,N,-diethylaminophenyl) sancycline, 7-(3-N,N,-dipropylaminophenyl) sancycline, and 7-(3-N,N,-dibutylaminophenyl) sancycline.

### Claim 44 (depends on 38)

The method of claim 38, wherein R7 is 4-substituted phenyl.

### Claim 45 (depends on 44)

The method of claim 44, wherein said compound is selected from the group consisting of 7-(4-fluorophenyl) sancycline, 7-(4-chlorophenyl) sancycline, 7-(4-bromophenyl) sancycline, 7-(4-iodophenyl) sancycline, 7-(4-trichloromethylphenyl) sancycline, 7-(4-trifluoromethylphenyl) sancycline, 7-(4-tribromomethylphenyl) sancycline, 7-(4-triiodomethylphenyl) sancycline, 7-(4-nitrophenyl) sancycline, 7-(4-aminophenyl) sancycline, 7-(4-N,N,-dimethylaminophenyl) sancycline, 7-(4-N,N,-diethylaminophenyl) sancycline, 7-(4-N,N,-dipropylaminophenyl) sancycline, and 7-(4-N,N,-dibutylaminophenyl) sancycline.

### Claim 46

A method for treating a tetracycline responsive state in a mammal, comprising administering to said mammal 7,9-diphenyl sancycline and pharmaceutically acceptable salts thereof, which is substantially free of positional isomers, such that the tetracycline responsive state is treated, wherein said 7,9-diphenyl sancycline is substantially free of positional isomers.

### Claim 47 (depends on 37, 46)

The method of claim 37 or 46, wherein said tetracycline responsive state is a bacterial infection.

### Claim 48 (depends on 47)

The method of claim 47, wherein said bacterial infection is associated with E. coli.

### Claim 49 (depends on 47)

The method of claim 47, wherein said bacterial infection is associated with S. aureus.

### Claim 50 (depends on 47)

The method of claim 47, wherein said bacterial infection is associated with E. faecalis.

### Claim 51 (depends on 47)

The method of claim 47, wherein said bacterial infection is resistant to other tetracycline antibiotics.

### Claim 52 (depends on 37, 46)

The method of claim 37 or 46, wherein said compound is administered with a pharmaceutically acceptable carrier.

### Claim 53 (depends on 37, 46)

The method of any one of claims 37 or 46, wherein said compound is at least 75% free of positional isomers.

### Claim 54 (depends on 53)

The method of claim 53, wherein said compound is at least 80% free of positional isomers.

### Claim 55 (depends on 54)

The method of claim 54, wherein said compound is at least 85% free of positional isomers.

### Claim 56 (depends on 55)

The method of claim 55, wherein said compound is at least 90% free of positional isomers.

### Claim 57 (depends on 56)

The method of claim 56, wherein said compound is at least 95% free of positional isomers.

### Claim 58 (depends on 1, 31)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or 31, and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 58)

The pharmaceutical composition of claim 58, wherein said compound is selected from the group consisting of 7-phenyl sancycline, 7,9 diphenylsancycline, 7-(2-fluorophenyl) sancycline, 7-(2-chlorophenyl) sancycline, 7-(2-bromophenyl) sancycline, 7-(2-iodophenyl) sancycline, 7-(3-fluorophenyl) sancycline, 7-(3-chlorophenyl) sancycline, 7-(3-bromophenyl) sancycline, 7-(3-iodophenyl) sancycline, 7-(4-fluorophenyl) sancycline, 7-(4-chlorophenyl) sancycline, 7-(4-bromophenyl) sancycline, 7-(4-iodophenyl) sancycline, 7-(4-trichloromethylphenyl) sancycline, 7-(4-trifluoromethylphenyl) sancycline, 7-(4-tribromomethylphenyl) sancycline, 7-(4-triiodomethylphenyl) sancycline, 7-(2-nitrophenyl) sancycline, 7-(2-aminophenyl) sancycline, 7-(2-N,N,-dimethylaminophenyl) sancycline, 7-(2-N,N,-diethylaminophenyl) sancycline, 7-(2-N,N,-dipropylaminophenyl) sancycline, 7-(2-N,N,-dibutylaminophenyl) sancycline, 7-(3-nitrophenyl) sancycline, 7-(3-aminophenyl) sancycline, 7-(3-N,N,-dimethylaminophenyl) sancycline, 7-(3-N,N,-diethylaminophenyl) sancycline, 7-(3-N,N,-dipropylaminophenyl) sancycline, 7-(3-N,N,-dibutylaminophenyl) sancycline, 7-(4-nitrophenyl) sancycline, 7-(4-aminophenyl) sancycline, 7-(4-N,N,-dimethylaminophenyl) sancycline, 7-(4-N,N,-diethylaminophenyl) sancycline, 7-(4-N,N,-dipropylaminophenyl) sancycline, and 7-(4-N,N,-dibutylaminophenyl) sancycline.

### Claim 60 (depends on 58)

The pharmaceutical composition of claim 58 wherein said compound is at least 75% free of positional isomers.

### Claim 61 (depends on 60)

The pharmaceutical composition of claim 60, wherein said compound is at least 80% free of positional isomers.

### Claim 62 (depends on 61)

The pharmaceutical composition of claim 61, wherein said compound is at least 85% free of positional isomers.

### Claim 63 (depends on 62)

The pharmaceutical composition of claim 62, wherein said compound is at least 90% free of positional isomers.

### Claim 64 (depends on 63)

The pharmaceutical composition of claim 63, wherein said compound is at least 95% free of positional isomers.
